Tempest Therapeutics Inc
Change company Symbol lookup
Select an option...
TPST Tempest Therapeutics Inc
PETV PetVivo Holdings Inc
KMI Kinder Morgan Inc
NXPL NextPlat Corp
D Dominion Energy Inc
CVS CVS Health Corp
CVI CVR Energy Inc
CTRE CareTrust REIT Inc
CSWC Capital Southwest Corp
CSCO Cisco Systems Inc

Health Care : Biotechnology |
Company profile

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Closing Price
Day's Change
-0.20 (-9.76%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Carvana seeks to reset after 2022 losses, plans $1 billion in cost reductions

7:54 am ET February 24, 2023 (MarketWatch)

By Wallace Witkowski

Company hopes to avoid layoffs as it attempts to right itself

Carvana Co. said it plans to complete a $1 billion reduction in operating costs by the second quarter of 2023 as the online car-sales company seeks to right itself without resorting to layoffs, after it snapped a streak of winning years in 2022.

Carvana (CVNA) shares fluctuated between slight gains and losses after hours, following a 0.1% gain in the regular session to close at $10.08.

"We expect these expense reductions to be broad-based across all large SG&A expense components, but importantly, we do not expect a reduction-in-force to be part of this plan," Carvana said in a statement.

"We came into the year positioned for growth, similar to what we had experienced in our prior nine years," the company told shareholders in a letter. "After the pandemic, snarled automotive supply chains and historically rapidly rising interest rates combined to dramatically impact the affordability of used cars."

"Rising interest rates and market sentiment drove a significant shift in our priorities away from growth and toward profitability," Carvana said. "This led to markedly lower volumes than we had positioned for and, as a result, we have been carrying excess costs."

The company reported a fourth-quarter loss of $806 million, or $7.61 a share, compared with a loss of $89 million, or $1.02 a share, in the year-ago period.

Carvana reported total revenue fell to $2.83 billion from $3.75 billion in the year-ago quarter, as retail sales fell 23% to 86,977 units.

Analysts surveyed by FactSet had forecast a loss of $2.18 a share on revenue of $3.06 billion.

"We currently expect a sequential reduction in retail units sold in Q1 2023 compared to Q4 2022, as we continue to normalize our inventory size, optimize marketing spend, and make progress on our profitability initiatives," the company said.

Carvana shares have jumped 112% year to date, but are still down 92% over the past 12 months.

-Wallace Witkowski


(END) Dow Jones Newswires

February 24, 2023 07:54 ET (12:54 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.